Amendments to the CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Ŧ

1. (Currently amended) A compound of the general formula (I),

$$R_{13}$$
 R_{14}
 R_{10}
 R_{12}
 R_{11}
 R_{12}
 R_{11}
 R_{12}
 R_{11}
 R_{12}
 R_{11}
 R_{12}
 R_{11}
 R_{12}
 R_{11}
 R_{12}
 R_{13}
 R_{14}
 R_{12}
 R_{11}
 R_{12}
 R_{13}
 R_{14}
 R_{12}
 R_{11}
 R_{12}
 R_{13}
 R_{14}
 R_{15}
 R_{15}

General formula (I)

ts derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts and solvates, wherein

R₀ is either hydrogen or a linear or branched (C₁-C₂)alkyl;

R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁ and R₁₂ may be are the same or different and are each independently represent selected from the group consisting of hydrogen, a halogen, a perhaloalkyl group, an amino group, a substituted or unsubstituted groups such as linear or branched chain (C₁-C₁₂)alkyl, (C₃-C₇)cycloalkyl, (C₁-C₁₂)alkoxy, cyclo(C₃-C₇)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, alkylthio, aminocarbonylamino, dialkylaminocarbonylamino, carboxylic acid and its derivatives thereof; [[,]]

R₁₃ and R₁₄ may be are the same or different and are each independently represents selected from the group consisting of hydrogen, a substituted or unsubstituted groups such as linear or branched chain (C₁-C₄)alkyl, (C₃-C₇)cycloalkyl, (C₃-C₇)cycloalkenyl, bicycloalkyl, bicycloalkenyl, aryl, and aralkyl[[,]] or optionally R₁₃ and R₁₄ along taken together with the nitrogen atom to which they are attached, may form a substituted or unsubstituted 3, 4, 5, 6 or 7-membered heterocyclic ring, wherein the ring may be further substituted, and it may have either wherein said ring contains from 0 to 3 one, two or three double bonds or "additional heteroatoms", as defined above and from 0 to 2 heteroatoms; and

"n" n is an integer ranging from 1 to 6.8, preferably 1 to 4. The carbon chains which `in` represents may be either linear or branched 6, wherein if n is an integer ranging from 3 to 6, the carbon chain is linear or branched,

or a derivative, analog, tautomeric form, stereoisomer, polymorph, pharmaceutically acceptable salt or solvate thereof.

- 2. (Currently amended) A <u>The</u> compound according to claim [[-]]1, which is selected from the group consisting of:
- 11-(2-N,N-Dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;
- 2-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole:
- 2-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole hydrochloride salt:
- 2-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2-,1-a]indole maleic acid salt;
- 2-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-is- oindolo[2,1-a]indole D,L-malic acid salt;
- 2-Chloro-11-(2-N,N-dimethylamino- ethyl)-6H-isoindolo[2,1-a]indole oxalate salt;
- 2-Chloro-11-(2-N,N-dimethyl- aminoethyl)-6H-isoindolo[2,1-a]indole citrate salt;
- 2-Fluoro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;
- 2-Chloro-11-(2-N,N-diethylaminoethyl)-6H-isoindolo[2,1-a]indole citrate salt;
- 2-Fluoro-11-(2-N,N-diethylaminoethyl)-6H-isoindolo[2,1-a]indole;
- 2-Chloro-11-(2-N-cyclopropyl-N-methylaminoethyl)-6H-isoindolo[2,1-a]indole citrate salt;
- 2-Fluoro-11-(2-N-cyclopropyl-N-methylaminoethyl)-6H-isoind-olo[2,1-a]indole;
- 11-(2-N,N-Dimethylaminoethyl)-2-methyl-6H-isoindolo[2,1-- a]indole;

```
11-(2-N,N-Dimethylaminoethyl)-2-methoxy-6H-isoindolo[2,1-a]indole;
```

- 2-Bromo-11-(2-N,N-diethylaminoethyl)-6H-isoindolo[2,1-a]indole;
- 2-Bromo-11-(2-N-methyl-N-cyclopropylaminoethyl)-6H-isoindolo[2,1-a]indole;
- 4-Chloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;
- 3,4-Dichloro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;
- 1-Chloro-11-(2-N,N-dimethylaminoethyl)-4methyl-6H-isoindolo[2,1-a]indole;
- 3-Chloro-11-(2-N,N-dimethylaminoethyl)-4methyl-6H-isoindolo[2,1-a]indole;
- 3-Chloro-11-[(2-N-methylamino)ethyl]-4-methyl-6H-isoindolo[2,1-a]indole;
- 3-Chloro-11-[(2-N-methyl-N-acetylamino)ethyl]-4methyl-6H-isoindolo[2,1-a]- indole;
- 3-Chloro-11-[(2-N-methylamino)ethyl]-2-methoxy-6H-isoindolo[2,1-a]- indole;
- 3-Chloro-11-[(2-N-methylamino)ethyl]-2-sulfoamido-6H-isoindolo[2,1-a]indole;
- 3-Iodo-11-[(2-N-methylamino)ethyl]-2-methoxy-6H-isoindolo[2,1-a]indole;
- 11-(2-N,N-Dimethylaminoethyl)-4-trifluoromethyl-6H-isoindolo[2,1-a]indole;
- 2,4-Difluoro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;
- 11-(2-Pyrrolidin-1-ylethyl)-6H-isoindolo[2,1-a]indole;
- 2-Bromo-11-(2-pyrrolidin-1-ylethyl)-6H-isoindolo[2,1-a]indole;
- 11-(2-(Piperidin-1-yl)ethyl)-6H-isoindolo[2,1-a]indole;
- 11-(2-(4-Methylpiperazin-1-yl)ethyl)-6H-isoindolo[2,1-a]indole;
- 11-(3-(Pyrrolidin-1-yl)-1-hydroxyprop-1-yl)-6H-isoindolo[2,1-a]indole;
- 2-Bromo-11-(3-(piperidin-1-yl)-1-hydroxyprop-1-yl)-6H-isoindolo[2,1-a]indole;
- 11-(2-N,N-Dimethylaminoethyl)-4-ethyl-6H-isoindolo[2,1-a]indole;
- 11-(2-N,N-Dimethylamino-1-hydroxyethyl)-6H-isoindolo[2,1-a]indole;
- 11-(2-N,N-Dimethylaminoethyl)-4-methoxy-6H-isoindolo[2,1-a]indole;
- 2-Bromo-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;
- 4-Bromo-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;
- 4-Fluoro-11-(2-N,N-dimethylaminoethyl)-6H-isoindolo[2,1-a]indole;
- 2-Bromo-11-(2-(4methylpiperazin-1-yl)ethyl)-6H-isoindolo[2,1-a]indole; and its stereoisomers, its N-oxides, its polymorphs, its pharmaceutically acceptable salts and solvates or a stereoisomer, N-oxide, polymorph, pharmaceutically acceptable salt or solvate thereof.

- 3. (Currently amended) A pharmaceutical composition comprising either of a pharmaceutically acceptable carrier, diluent/s diluent, excipient/s excipient or solvates solvent and along with a therapeutically effective amount of a compound according to claim[[-]]1, its derivatives, its analogs, its tautomeric forms, its stereoisomers, its geometric forms, its N oxides, its polymorphs, its pharmaceutically acceptable salts, or solvates.
- 4. (Currently amended) A <u>The pharmaceutical composition according to claim[[-]]3, which is in the form of a tablet, a capsule, a powder, lozenges, suppositories, a lozenge, a suppository, a syrup, a solution, a suspension or injectable an injection, wherein said form is administered in, as a single dose or in multiple dose units.</u>
- 5. (Cancelled)
- 6. A method of modulating Use of compound of general formula (I), as defined in claim 1 or a pharmaceutical composition as defined in claim 3 for the treatment where a modulation of 5-HT and melatonin activity is desired in a patient, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1.
- 7. (Currently amended) A method of selectively modulating the 5-HT receptors of a patient, comprising administering to said patient Use of a therapeutically effective amount of a compound as elaimed in according to claim[[-]]1 for the manufacture of a medicament for the treatment and/or prevention of clinical conditions for which a selective action on 5-HT receptors is indicated.
- 8-11. (Cancelled)
- 12. (Currently amended) Use of a radiolabelled compound as claimed in claim-1, as a diagnostic tool for A method of modulating 5-HT receptor function in a patient, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1, wherein the

compound is isotopically labeled.

13. (Currently amended) The pharmaceutical composition according to claim 3, further comprising Use of a compound as claimed in claims 1 in combination with a therapeutically effective amount of a 5-HT re-uptake inhibitor, melatonin, a melatoninergic modulator and/or a pharmaceutically acceptable salt thereof.

14. (Cancelled)

- 15. (Currently amended) A method for the treatment and/or prophylaxis of elinical conditions such as anxiety, depression, convulsive disorders, obsessive-compulsive disorders, migraine headache, cognitive memory disorders, ADHD (Attention Deficient Disorder/Hyperactivity Syndrome), personality disorders, psychosis, paraphrenia, psychotic depression, mania, schizophrenia, schizophreniform disorders, withdrawal from drug abuse, panic attacks, reproduction, glaucoma, sleep disorders and also or disorders associated with spinal trauma and/or head injury in a patient, which comprises administering to [[a]] said patient in need thereof[[, an]] a therapeutically effective amount of a compound of general formula (I) as claimed in Claim-1 according to claim 1.
- 16. (Currently amended) A method for the treatment and/or prophylaxis of mild cognitive impairment, and other neurodegenerative disorders like Alzheimer's disease, Parkinsonism and or Huntington's chorea in a patient, which comprises administering to [[a]] said patient in need thereof[[, an]] a therapeutically effective amount of a compound of general formula (I) as claimed in Claim-1 according to claim 1.
- 17. (Currently amended) A method for the treatment of certain GI (Gastrointestinal) disorders such as IBS (Irritable irritable bowel syndrome) or chemotherapy induced emesis using a compound of general formula (I) as claimed in Claim-1 in a patient, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1.

18. (Currently amended) A method to reduce of reducing in a patient morbidity and mortality associated with the excess weight using a compound of general formula (I) as claimed in Claim-1, comprising administering to the patient a therapeutically effective amount of a compound according to claim 1.

19. (Cancelled)